Ancora Biotech
Company Details
Status: Private
Employees: 11-50
Location:
Palo Alto, California, United States
Type:
sample
Technology:
sample
sample
About: Ancora Biotech LLC is a privately held company supporting the clinical development of three multi-specific antibodies. These three antibodies are held in separate spin-offs, namely: 1) TeneoTwo holds our clinical stage TNB-486 (anti-CD19xCD3) T cell engager for the safe and effective treatment of B cell cancers, 2) TeneoFour holds our preclinical TNB-738 (anti-CD38) enzyme inhibitor for the treatment of inflammatory and metabolic disorders in the elderly, and 3) TeneoTen holds our preclinical T cell engager (anti-HBVxCD3) for the curative treatment of chronic hepatitis B infections (CHB). TNB-738 is poised to enter Phase I clinical studies by early 2022 and we anticipate to select a clinical lead for CHB by mid-2022.
Certain former executives and former shareholders of Teneobio, including Lightspeed Venture Partners and Sutter Hill Ventures, have formed Ancora Biotech to oversee all manufacturing and clinical development of these assets.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Ancora Biotech | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.